Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,093 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.
Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Kunz PL, et al. Among authors: messina m. Invest New Drugs. 2012 Dec;30(6):2364-70. doi: 10.1007/s10637-012-9800-3. Epub 2012 Feb 14. Invest New Drugs. 2012. PMID: 22331549 Free PMC article. Clinical Trial.
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC. Richardson PG, et al. Among authors: messina m. Br J Haematol. 2011 Jun;153(6):729-40. doi: 10.1111/j.1365-2141.2011.08664.x. Epub 2011 Apr 28. Br J Haematol. 2011. PMID: 21534941 Free article. Clinical Trial.
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.
Revicki DA, van den Eertwegh AJ, Lorigan P, Lebbe C, Linette G, Ottensmeier CH, Safikhani S, Messina M, Hoos A, Wagner S, Kotapati S. Revicki DA, et al. Among authors: messina m. Health Qual Life Outcomes. 2012 Jun 13;10:66. doi: 10.1186/1477-7525-10-66. Health Qual Life Outcomes. 2012. PMID: 22694829 Free PMC article. Clinical Trial.
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies.
Cale EM, Shen CH, Olia AS, Radakovich NA, Rawi R, Yang Y, Ambrozak DR, Bennici AK, Chuang GY, Crooks ED, Driscoll JI, Lin BC, Louder MK, Madden PJ, Messina MA, Osawa K, Stewart-Jones GBE, Verardi R, Vrakas Z, Xie D, Zhang B, Binley JM, Connors M, Koup RA, Pierson TC, Doria-Rose NA, Kwong PD, Mascola JR, Gorman J. Cale EM, et al. Among authors: messina ma. Cell Rep. 2024 Dec 24;43(12):115010. doi: 10.1016/j.celrep.2024.115010. Epub 2024 Dec 14. Cell Rep. 2024. PMID: 39675002 Free article.
Water beads: Expanding toy and 'new' problem for paediatric surgeons and community.
Bollettini T, Mogiatti M, Benigna A, Finelli A, Ferrara F, Pardi V, Macchiarelli R, Messina M, Gentilino V, Molinaro F, Angotti R. Bollettini T, et al. Among authors: messina m. J Paediatr Child Health. 2024 Dec 7. doi: 10.1111/jpc.16730. Online ahead of print. J Paediatr Child Health. 2024. PMID: 39644294
1,093 results